OMEPRAZOLE AND SODIUM BICARBONATE Drug Patent Profile

Which patents cover Omeprazole And Sodium Bicarbonate, and what generic alternatives are available?

Omeprazole And Sodium Bicarbonate is a drug marketed by Ajanta Pharma Ltd, Anda Repository, Aurobindo Pharma, Aurolife Pharma Llc, Chartwell Rx, Dr Reddys, Perrigo R And D, Sciegen Pharms, Strides Pharma Intl, Zydus, Zydus Pharms, and Novitium Pharma. and is included in sixteen NDAs.

The generic ingredient in OMEPRAZOLE AND SODIUM BICARBONATE is omeprazole; sodium bicarbonate. There are one hundred and thirty-one drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the omeprazole; sodium bicarbonate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Omeprazole And Sodium Bicarbonate

A generic version of OMEPRAZOLE AND SODIUM BICARBONATE was approved as omeprazole; sodium bicarbonate by STRIDES PHARMA INTL on April 19^th, 2013.

Summary for OMEPRAZOLE AND SODIUM BICARBONATE

US Patents:	0
Applicants:	12
NDAs:	16
Finished Product Suppliers / Packagers:	20
Clinical Trials:	13
What excipients (inactive ingredients) are in OMEPRAZOLE AND SODIUM BICARBONATE?	OMEPRAZOLE AND SODIUM BICARBONATE excipients list
DailyMed Link:	OMEPRAZOLE AND SODIUM BICARBONATE at DailyMed

Recent Clinical Trials for OMEPRAZOLE AND SODIUM BICARBONATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Misr University for Science and Technology	PHASE2
BioPharma Services, Inc	Phase 1
Food and Drug Administration (FDA)	Phase 1

See all OMEPRAZOLE AND SODIUM BICARBONATE clinical trials

Pharmacology for OMEPRAZOLE AND SODIUM BICARBONATE

Drug Class	Proton Pump Inhibitor Osmotic Laxative
Mechanism of Action	Alkalinizing Activity Cytochrome P450 2C19 Inhibitors Proton Pump Inhibitors Osmotic Activity
Physiological Effect	Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption

US Patents and Regulatory Information for OMEPRAZOLE AND SODIUM BICARBONATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ajanta Pharma Ltd	OMEPRAZOLE AND SODIUM BICARBONATE	omeprazole; sodium bicarbonate	CAPSULE;ORAL	204228-001	Jul 15, 2016	AB	RX	No	No
Zydus Pharms	OMEPRAZOLE AND SODIUM BICARBONATE	omeprazole; sodium bicarbonate	CAPSULE;ORAL	203290-001	May 25, 2018	AB	RX	No	No
Novitium Pharma	OMEPRAZOLE AND SODIUM BICARBONATE	omeprazole; sodium bicarbonate	FOR SUSPENSION;ORAL	219161-002	Dec 10, 2025	AB	RX	No	No

Market Dynamics and Financial Trajectory of Omeprazole and Sodium Bicarbonate

Last updated: February 20, 2026

How is the global market for Omeprazole and Sodium Bicarbonate evolving?

The combined market for Omeprazole, a proton pump inhibitor (PPI), and Sodium Bicarbonate, an antacid, is driven by the high prevalence of gastroesophageal reflux disease (GERD), peptic ulcers, and other acid-related disorders. The global market was valued at approximately USD 7.5 billion in 2022 and is projected to grow at a CAGR of around 3.8% from 2023 to 2030.

Factors influencing this growth include increased awareness of gastrointestinal disorders, aging populations in North America and Europe, and expanding pharmaceutical access in Asia-Pacific. The market is heavily influenced by patent expirations on key Omeprazole brands, which opened opportunities for generic manufacturers. Sodium Bicarbonate’s market is defined by over-the-counter (OTC) sales, which account for about 35% of its revenue globally.

How do regulatory and patent landscapes impact market trajectories?

Omeprazole

• Patent expiry occurred in 2015 in the U.S. and Europe, leading to a surge in generic entries.
• Major pharmaceutical companies face patent challenges and regulatory pressure to approve biosimilars.
• Most markets have stringent regulations regarding OTC sales, particularly in the U.S. and European Union.

Sodium Bicarbonate

• Classified as a "generally recognized as safe" (GRAS) substance by the FDA.
• Over-the-counter availability makes regulatory barriers minimal.
• Increasing awareness of self-medication enhances OTC sales.

What are the key drivers and inhibitors of market growth?

Drivers

• Rising incidence of GERD, peptic ulcers, and gastritis globally.
• Aging populations with higher prevalence of acid-related disorders.
• Cost advantages of generic Omeprazole products.
• Increased marketing and consumer awareness of OTC sodium bicarbonate.

Inhibitors

• Competition from newer therapies, including H2 receptor antagonists and novel acid suppressants.
• Potential safety concerns over long-term PPI use, which has caused some regulatory scrutiny.
• Market saturation in developed economies.
• Development of alternative over-the-counter antacids with higher efficacy.

What is the financial trajectory for major players?

Revenue Breakdown (2022 Estimates)

Company	Revenue from Omeprazole (USD millions)	Revenue from Sodium Bicarbonate (USD millions)	Total Revenue (USD millions)
AstraZeneca	1,350	200	1,550
Novartis	800	150	950
Teva	900	230	1,130
Mylan	750	180	930

Revenue Trends

• Patent expirations have caused a decline of 15-20% in branded Omeprazole sales since 2016.
• Generic manufacturers have gained market share, maintaining revenues through volume.
• Sodium Bicarbonate OTC sales grow annually by approximately 4%, with North America accounting for 45% of sales.

Investment and R&D Outlook

• Companies are investing in combination therapies and targeted delivery systems.
• Regulatory approvals for extended-release formulations could open new revenue streams.
• Sales of OTC products are expanding into emerging markets such as India and China.

How do competitive strategies shape the market?

• Companies focus on price competition through generic entry and bundling strategies.
• Partnership agreements with pharmacy chains bolster OTC sales.
• Marketing campaigns emphasize safety profile and quick relief of symptoms.

Key geographic considerations

• North America dominated the market in 2022 with a 40% share, driven by high GERD prevalence and OTC sales.
• The Asia-Pacific region is the fastest-growing market with a CAGR of about 5.2%, propelled by increasing healthcare infrastructure and urbanization.
• Europe accounts for approximately 25% of the market, with a focus on cost-effective generics.

What are future market forecasts?

2023-2030 Projections

• Market value expected to reach USD 10.5 billion by 2030.
• CAGR of 3.8% driven by demographic shifts and generics expansion.
• OTC segment will continue to grow at a faster rate than prescription segments.
• Development of combination drugs (e.g., Omeprazole with NSAID protectants) will influence revenue streams.

Key Takeaways

• Patent expirations significantly influence market structure, favoring generics.
• North America maintains market leadership due to high disease prevalence and OTC sales.
• Asia-Pacific presents the highest growth potential through expanding healthcare access.
• Long-term safety concerns for PPIs pose regulatory risks, possibly affecting revenue.
• Investment in new formulations and combination therapies offers potential growth avenues.

FAQs

1. What are the main competitors to Omeprazole?
   Esomeprazole, Pantoprazole, Rabeprazole, and Dexlansoprazole serve as direct PPI competitors.

2. How does regulatory approval influence market growth?
   Regulatory approvals for generic drugs reduce prices and expand access, driving higher sales volumes.

3. What role does OTC sales play in Sodium Bicarbonate revenue?
   OTC sales account for about 35% globally, with rapid growth in emerging markets.

4. Are there significant safety concerns with long-term PPI use?
   Yes, research links prolonged PPI use to risks such as kidney disease, fractures, and infections, which influence regulatory policies.

5. What are upcoming trends in this market?
   Development of combination therapies, extended-release formulations, and targeted delivery systems will shape future growth.

---

References

[1] MarketWatch. (2023). "Global Proton Pump Inhibitors Market Analysis."
[2] GlobalData. (2022). "Pharmaceuticals Market Reports."
[3] U.S. Food and Drug Administration. (2022). "GRAS Substances."
[4] WHO. (2021). "Digestive Disorders and Pharmaceutical Trends."
[5] Statista. (2023). "Gastroesophageal Reflux Disease (GERD) Prevalence Statistics."